Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma

被引：6

作者：

Li, Shuchan ^{[1
,2
]}

Zheng, Gaofeng ^{[1
,2
]}

He, Jingsong ^{[1
,2
]}

Wu, Wenjun ^{[1
,2
]}

Chen, Qingxiao ^{[1
,2
]}

Yang, Yang ^{[1
,2
]}

He, Donghua ^{[1
,2
]}

Zhao, Yi ^{[1
,2
]}

Han, Xiaoyan ^{[1
,2
,3
]}

Cai, Zhen ^{[1
,2
,3
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Zhejiang, Peoples R China

[2] Zhejiang Univ, Inst Hematol, Hangzhou, Zhejiang, Peoples R China

[3] Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, 79 Qingchun Rd, Hangzhou, Zhejiang, Peoples R China

来源：

LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 04期

基金：

中国国家自然科学基金;

关键词：

Multiple myeloma; daratumumab; cytomegalovirus; Epstein-Barr virus; STEM-CELL TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; PREEMPTIVE RITUXIMAB; RISK-FACTORS; REACTIVATION; RECIPIENTS; DISEASE; BORTEZOMIB; THERAPY; VIREMIA;

D O I：

10.1080/10428194.2023.2172982

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We explored the incidence of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections in 131 patients with multiple myeloma (MM), 53 of whom received daratumumab (Dara) treatments. The Dara group had more RRMM patients than the group without Dara. CMV infection was significantly more common in patients treated with Dara (16.98%) than in patients treated with regimens without Dara (2.56%). During Dara treatments, 24.53% of patients developed CMV and/or EBV infections. Patients who developed infections had significantly lower levels of albumin and lymphocytes in their peripheral blood. The median time from the first Dara infusion to infection was 27 days. We observed NK cell depletion and T cell expansion during Dara-treatment. Patients with CMV and/or EBV infections had significantly lower numbers of NK cells, total T cells, and CD8 + T cells at 1 month, and lower numbers of CD8 + T cells at 2 months after the first Dara infusion than those without infections.

引用

页码：835 / 845

页数：11

共 57 条

[1] Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell Transplantation [J].

Ahmad, Imran ;

Cau, Nguyen V. ;

Kwan, John ;

Maaroufi, Younes ;

Meuleman, Nathalie ;

Aoun, Mickael ;

Lewalle, Philippe ;

Martiat, Philippe ;

Crokaert, Francoise ;

Bron, Dominique .

TRANSPLANTATION, 2009, 87 (08) :1240-1245

[2] Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party [J].

Augustson, BM ;

Begum, G ;

Dunn, JA ;

Barth, NJ ;

Davies, F ;

Morgan, G ;

Behrens, J ;

Smith, A ;

Child, JA ;

Drayson, MT .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9219-9226

[3] Relapsed refractory multiple myeloma: a comprehensive overview [J].

Bazarbachi, Abdul Hamid ;

Al Hamed, Rama ;

Malard, Florent ;

Harousseau, Jean-Luc ;

Mohty, Mohamad .

LEUKEMIA, 2019, 33 (10) :2343-2357

[4] Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients [J].

Blimark, Cecilie ;

Holmberg, Erik ;

Mellqvist, Ulf-Henrik ;

Landgren, Ola ;

Bjoekholm, Magnus ;

Hultcrantz, Malin ;

Kjellander, Christian ;

Turesson, Ingemar ;

Kristinsson, Sigurdur Y. .

HAEMATOLOGICA, 2015, 100 (01) :107-113

[5] Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT [J].

Burns, D. M. ;

Rana, S. ;

Martin, E. ;

Nagra, S. ;

Ward, J. ;

Osman, H. ;

Bell, A. I. ;

Moss, P. ;

Russell, N. H. ;

Craddock, C. F. ;

Fox, C. P. ;

Chaganti, S. .

BONE MARROW TRANSPLANTATION, 2016, 51 (06) :825-832

[6] Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation [J].

Carpenter, Ben ;

Haque, Tanzina ;

Dimopoulou, Maria ;

Atkinson, Claire ;

Roughton, Michael ;

Grace, Sarah ;

Denovan, Shari ;

Fielding, Adele ;

Kottaridis, Panagiotis D. ;

Griffiths, Paul ;

Mackinnon, Stephen ;

Emery, Vincent ;

Chakraverty, Ronjon .

TRANSPLANTATION, 2010, 90 (05) :564-570

[7] Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma [J].

Casneuf, Tineke ;

Xu, Xu Steven ;

Adams, Homer C., III ;

Axel, Amy E. ;

Chiu, Christopher ;

Khan, Imran ;

Ahmadi, Tahamtan ;

Yan, Xiaoyu ;

Lonial, Sagar ;

Plesner, Torben ;

Lokhorst, Henk M. ;

van de Donk, Niels W. C. J. ;

Clemens, Pamela L. ;

Sasser, A. Kate .

BLOOD ADVANCES, 2017, 1 (23) :2105-2114

[8] Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens [J].

Chellapandian, DeepakBabu ;

Das, Rupali ;

Zelley, Kristin ;

Wiener, Susan J. ;

Zhao, Huaqing ;

Teachey, David T. ;

Nichols, Kim E. .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (03) :376-382

[9] Adapted Treatment of Epstein-Barr Virus Infection to Prevent Posttransplant Lymphoproliferative Disorder After Heart Transplantation [J].

Choquet, S. ;

Varnous, S. ;

Deback, C. ;

Golmard, J. L. ;

Leblond, V. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (04) :857-866

[10] Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States [J].

Cohen, Jeffrey I. ;

Jaffe, Elaine S. ;

Dale, Janet K. ;

Pittaluga, Stefania ;

Heslop, Helen E. ;

Rooney, Cliona M. ;

Gottschalk, Stephen ;

Bollard, Catherine M. ;

Rao, V. Koneti ;

Marques, Adriana ;

Burbelo, Peter D. ;

Turk, Siu-Ping ;

Fulton, Rachael ;

Wayne, Alan S. ;

Little, Richard F. ;

Cairo, Mitchell S. ;

El-Mallawany, Nader K. ;

Fowler, Daniel ;

Sportes, Claude ;

Bishop, Michael R. ;

Wilson, Wyndham ;

Straus, Stephen E. .

BLOOD, 2011, 117 (22) :5835-5849

← 1 2 3 4 5 6 →